ROCHESTER, N.Y., Aug. 22, 2012 /PRNewswire/ -- Caliber Imaging & Diagnostics, formerly Lucid, Inc. (OTC Bulletin Board: LCDX), the leader in Rapid Cell Imaging and Diagnostics technology, today announced the release of two next-generation products in its FDA-cleared VivaScope® family. The new VivaScope 1500 and VivaScope 3000 produce high-quality images of living cells at the point of care. VivaScope imagers enable physicians to perform painless "optical" biopsies to diagnose disease, by providing dynamic native views of the area of interest. In addition, VivaScope products can be used by research and development teams for claims validation as well as research into skin disease.
Both the VivaScope 1500 and 3000 have the advantage of Caliber ID's Rapid Cell Imaging and Diagnostics technology that shows cellular detail with a resolution comparable to standard histology. Changes in the new VivaScope products include the availability of a touch-screen monitor and a multi-touch software interface that enables physicians to navigate images quickly and with the same ease as popular touch screen devices. Additionally, the Company has introduced redesigned optics and electronics for enhanced image quality and improved speed of data acquisition.
"Our Rapid Cell Imaging and Diagnosis [Rapid Cell ID] technology enables physicians to perform fast, accurate and painless 'optical biopsies' of skin," notes William J. Fox, Chief Technology Officer and Vice President of Engineering. "We have moved imaging and diagnosis out of the lab and to the point and time of care. The data shows that, in many cases, the use of our technology can eliminate the need for an invasive procedure on healthy skin, reducing costs and associated risks. The patients that we speak with love our Rapid Cell ID technology, because it's noninvasive, fast and painless with no scarring and no recuperation time!"
The VivaScope 3000 is a handheld device and offers both a small probe interface and faster imaging. The VivaScope 3000 is intended for imaging and diagnosis at the point of care and it is especially useful for hard to reach areas such as around the eyes, nose, and ears. Weighing less than 32 ounces, the VivaScope 3000 allows a physician to rapidly assess skin lesions and determine a therapeutic course of action. Current users of the VivaScope 1500 can add the capabilities of the VivaScope 3000 as an accessory to an existing device installation.
The new VivaScope 1500 enables skin cancer specialists to capture the breadth and depth of a suspicious lesion with accuracy and reliable results. In addition, the VivaScope 1500 can also be utilized for applications such as cosmetic and personal care product development, product claims validation, disease research, clinical diagnosis of skin cancers and other skin disorders, and the identification of skin characteristics, including evaluation of how they respond to external changes. Areas of interest of up to 8 mm2 can be mapped through a combination of integrated tissue stabilization and automated software routines.
The Company is currently accepting orders of the new generation devices, with delivery scheduled for the fall of 2012.
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics (Caliber ID) platform of products offer increased productivity from the doctor's office to the surgeon's operating room. Today, the future of skin cancer diagnosis is here: an integrated platform of tools and technology for accurate diagnoses quickly and routinely. Caliber ID products provide precise accuracy, consistent reliability, and online backup that all combine to lead to life-saving early diagnosis. Wherever you are in the continuum of skin imaging and diagnosis, this is not just best in class. This is a new class. For more information about Caliber ID and its products, please visit www.caliberid.com.
VivaScope® is a registered trademark of Caliber Imaging & Diagnostics.
This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes," "assumes" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the SEC.